Core Viewpoint - He Yuan Biotechnology (Shanghai) Co., Ltd. forecasts a net loss of between 237 million yuan and 195 million yuan for 2025, representing a reduction in losses by 84.81 million yuan to 127 million yuan compared to the previous year [1] Group 1: Company Performance - The company has been deeply engaged in the cell and gene therapy (CGT) field for over a decade, developing core technology clusters for vector development, production processes, and quality control [1] - As of the end of 2025, He Yuan has assisted clients in obtaining over 60 clinical trial approvals, with 14 approvals granted by the U.S. Food and Drug Administration [1] - The company has established a million-level cell bank with one-click access and full visual management, along with 14 fully automated production lines in the regenerative medicine sector [1] Group 2: Technological Advancements - Continuous investment in technology has created a differentiated competitive barrier for the company [2] - In 2025, He Yuan's viral vector upgrades, including the VPack packaging system and AAV-PANX products, are expected to achieve high production [2] - The company has introduced proprietary technologies in gene editing and nucleic acid delivery, including the micro-light gene Cas12 protein and LNP-mRNA delivery system licensing [2] Group 3: Industry Position - Analysts indicate that He Yuan, with its comprehensive service capabilities and scalable delivery systems, has secured a favorable position in the CGT industrialization process [2] - The company's ongoing investments in technology, production capacity, and ecosystem collaboration are expected to further solidify its industry-leading position and contribute to the long-term development of the cell and gene therapy sector [2]

Core Viewpoint - The company, He Yuan Biotechnology (Shanghai) Co., Ltd., anticipates a net loss for the year 2025, although the loss is expected to be reduced compared to the previous year, indicating a potential improvement in financial performance despite ongoing challenges in the industry [2][4]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between -237 million to -195 million yuan for 2025, representing a reduction in loss of 84.81 million to 126.81 million yuan compared to the previous year, with a decrease in loss margin of 26.35% to 39.41% [2][4]. - The anticipated net profit, excluding non-recurring gains and losses, is projected to be between -244 million to -201 million yuan, reflecting a reduction in loss of 91.91 million to 134.91 million yuan year-on-year, with a decrease in loss margin of 27.36% to 40.16% [2][4]. Group 2: Previous Year Performance - In 2024, the total profit was -312.63 million yuan, with a net profit attributable to shareholders of the parent company at -321.81 million yuan, and a net profit excluding non-recurring gains and losses at -335.91 million yuan [6]. Group 3: Reasons for Performance Changes - The company is focusing on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field. The operational strategy emphasizes enhancing customer resource reserves, brand influence, and industry development [8]. - Despite an overall increase in revenue across various business segments, the CDMO business continues to face challenges such as insufficient downstream investment and low customer order prices, leading to significant losses [9]. - The company has conducted preliminary impairment tests on inventory, long-term assets, and contract orders due to the ongoing losses in the CDMO business, which has impacted the current net profit [10].

Core Viewpoint - He Yuan Bio announced an expected net profit attributable to the parent company for the year 2025 to be between -237 million to -195 million yuan, indicating a reduction in losses compared to the previous year [2] Financial Performance - The company anticipates a reduction in losses by 84.81 million to 126.81 million yuan, representing a decrease in loss margin of 26.35% to 39.41% compared to the same period last year [2] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -244 million to -201 million yuan, with a reduction in losses of 91.91 million to 134.91 million yuan, reflecting a decrease in loss margin of 27.36% to 40.16% year-on-year [2]

Core Viewpoint - The company expects to report a net loss attributable to shareholders for the year 2025, with projections ranging from -237 million to -195 million yuan, indicating a reduction in losses compared to the previous year [1] Financial Performance - The anticipated net loss represents a decrease in losses by 84.81 million to 126.81 million yuan compared to the same period last year [1] - The reduction in loss percentage is estimated to be between 26.35% and 39.41% [1]

Core Viewpoint - The company, Heyuan Bio (688238.SH), expects to reduce its net loss for the year 2025, projecting a net profit attributable to shareholders of between -237 million to -195 million yuan, representing a reduction in loss of 84.81 million to 127 million yuan compared to the previous year, with a decrease in loss margin of 26.35% to 39.41% [1] Financial Projections - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -244 million to -201 million yuan, which indicates a reduction in loss of 91.91 million to 135 million yuan compared to the previous year, with a decrease in loss margin of 27.36% to 40.16% [1]

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -237 million to -195 million CNY, a reduction in loss of 84.81 million to 126.81 million CNY compared to the previous year, representing a decrease in loss of 26.35% to 39.41%[2] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -244 million to -201 million CNY, a reduction in loss of 91.91 million to 134.91 million CNY compared to the previous year, indicating a decrease in loss of 27.36% to 40.16%[2] - The total profit for the year 2024 was -312.63 million CNY, with a net profit attributable to shareholders of the parent company at -321.81 million CNY[4] - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be disclosed in the audited annual report for 2025[8] Business Strategy - The company is focusing on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field[5] - The company aims to enhance customer resource reserves, improve brand influence, and promote industry development as part of its operational strategy[5] Industry Challenges - Despite a recovery in the cell and gene therapy industry starting in the second half of 2025, the CDMO business continues to face challenges due to insufficient downstream investment and financing, resulting in low customer order prices[6] - The company has conducted preliminary impairment testing on inventory, long-term assets, and contract orders due to the ongoing losses in the CDMO business, which has impacted the current net profit[6]

Core Viewpoint - The company, Heyuan Bio, has announced a projected net loss for the fiscal year 2025, estimating a loss between 237 million yuan and 195 million yuan, although this represents a narrowing of losses compared to the previous year [1] Group 1: Business Impact - The domestic biopharmaceutical sector is experiencing a complex landscape of opportunities and challenges, characterized by diversified development and intense market competition [1] - The company is focusing on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] - During the reporting period, all business segments of the company saw varying degrees of revenue growth, with a recovery in the cell and gene therapy industry expected in the second half of 2025 [1] Group 2: Operational Strategy - The company is prioritizing the enhancement of customer resource reserves, brand influence, and industry development, aiming to improve operational management capabilities and reduce costs [1] - Despite the planned advancement of the CDMO business, external factors such as insufficient downstream financing have impacted customer order prices, which remain at low levels compared to previous years [1] - The CDMO business has seen some improvement in gross margins, but high fixed operational costs related to depreciation, energy consumption, and daily maintenance have resulted in significant losses [1] Group 3: Impairment Provisions - Due to the ongoing losses in the cell and gene therapy CDMO business, the company has conducted preliminary impairment tests in accordance with accounting standards [1] - The company has made provisions for impairment related to inventory, long-term assets, and contract orders, which have negatively impacted the current net profit [1]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Group 1 - The company Anxing Zhenghe (Changsha) Biotechnology Co., Ltd. has been established with a registered capital of 5 million RMB [1] - The legal representative of the company is Yin Shan, and it is jointly held by Heyuan Biotechnology (Shanghai) Co., Ltd. (67% ownership) and Changsha Duozheng Medical Testing Co., Ltd. (33% ownership) [1] - The business scope includes the production and operation of various medical devices, drug import and export, and research and development in cell technology and human stem cell technology [1] Group 2 - The company is classified under the manufacturing industry, specifically in the pharmaceutical manufacturing sector [1] - The registered address of the company is located at 1058 Wenxuan Road, Lugu Street, Xiangjiang New District, Hunan [1] - The business license is valid until January 5, 2026, with no fixed expiration date [1]

Group 1 - The core focus is on enhancing the role of technology innovation and industrial development in Shanghai, particularly in the context of the "14th Five-Year Plan" and the city's modernization efforts [1][3] - Zhangjiang Science City is identified as a key area for building an international science and technology innovation center, with initiatives aimed at optimizing innovation layout and nurturing strategic technological capabilities [2][3] - The establishment of the Zhangjiang Artificial Intelligence Innovation Town has attracted nearly 500 AI companies, emphasizing the importance of aligning high-tech enterprises with the city's industrial positioning and development direction [2][3] Group 2 - The "14th Five-Year Plan" emphasizes the need for Zhangjiang to strengthen its role in technology innovation and to foster world-class enterprises and industry clusters [3] - There is a focus on enhancing the innovation ecosystem and providing support for startups, particularly in the fields of cell and gene therapy, to boost their core competitiveness [3][4] - The city aims to improve regulatory frameworks and service efficiency to better support enterprises in their innovation and growth efforts [4]